Corpus overview


Overview

MeSH Disease

Human Phenotype

Pneumonia (304)

Fever (167)

Cough (107)

Hypertension (91)

Respiratory distress (91)


Transmission

age categories (586)

Transmission (495)

asymptotic cases (252)

gender (244)

fomite (192)


Seroprevalence
    displaying 1341 - 1350 records in total 2851
    records per page




    Serial Interval TRANS Distribution of SARS-CoV-2 Infection MESHD in Brazil

    Authors: Carlos A. Prete Jr.; Lewis Buss; Amy Dighe; Victor Bertollo Porto; Darlan da Silva Candido; Fabio Ghilardi; Oliver G. Pybus; Wanderson Kleber de Oliveira; Julio H. R. Croda; Ester Cerdeira Sabino; Nuno R. Faria; Christl A. Donnelly; Vitor Heloiz Nascimento

    doi:10.1101/2020.06.09.20127043 Date: 2020-06-12 Source: medRxiv

    Using 65 transmission TRANS pairs of SARS-CoV-2 reported to the Brazilian Ministry of Health we estimate the mean and standard deviation for the serial interval TRANS to be 2.97 and 3.29 days respectively. We also present a model for the serial interval TRANS probability distribution using only two parameters.

    Life-threatening cardiogenic shock HP cardiogenic shock MESHD in a pediatric patient with SARS-CoV-2-associated myocarditis HP myocarditis MESHD treated with remdesivir: a case description and report of similar cases from the Literature

    Authors: Silvia Molinari; Lucia M.D. Colasanto; Maria L. Melzi; Alessandro Cattoni; Roberto Panceri; Michela Bombino; Giuseppe Lapadula; Andrea Biondi

    doi:10.21203/rs.3.rs-34802/v1 Date: 2020-06-12 Source: ResearchSquare

    BackgroundChildren are relatively spared from Coronavirus disease MESHD 2019 (COVID-19), but some severe cases have been reported. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection MESHD in children TRANS may affect the cardiovascular system. We hereby report about a case of myocarditis HP myocarditis MESHD evolving to cardiogenic shock HP cardiogenic shock MESHD in a SARS-CoV-2 positive child TRANS.Case presentationAn otherwise healthy 12-year-old patient was admitted with fever HP fever MESHD, vomiting HP vomiting MESHD, diarrhoea and drowsiness MESHD drowsiness HP, without any respiratory symptoms. He was diagnosed with COVID-19 on nasopharyngeal swab. He developed hypotension HP hypotension MESHD and cardiogenic shock HP cardiogenic shock MESHD. Bedside echocardiography revealed left ventricular impairment MESHD with an ejection fraction (LVEF) below 25%. Plasmatic markers of myocardial injury MESHD were remarkably raised, as well as inflammatory biomarkers, including procalcitonin (highest recorded value: 66 ng/mL) and interleukin-6 (8209 pg/mL). The child TRANS was transferred to Intensive Care Unit and he was treated with catecholamine support, mechanical ventilation and empiric anti-infectious therapy, including broad spectrum antibiotics and the antiviral agent remdesivir. All additional microbiological investigations yielded negative results. We observed a gradual improvement of LVEF within 5 days. A cardiac magnetic resonance confirmed the suspicion of myocarditis HP myocarditis MESHD. After 21 days of hospitalisation, the child TRANS was discharged without sequelae.ConclusionsOur hypothesis is that the child TRANS suffered from SARS-CoV-2-induced fulminant myocarditis HP myocarditis MESHD, probably in the setting of cytokine release syndrome (CRS). The peculiarity of this SARS-CoV-2 infection MESHD is the presence of cardiac failure MESHD in a previously healthy child TRANS without a respiratory illness MESHD. The positive outcome is in line with published Literature about the overall better prognosis of COVID-19 children TRANS compared to adults TRANS. Remdesivir, an investigational antiviral therapy, may have played a role on the clinical improvement of the child TRANS.

    Shielding and Beyond: The Roles of Glycans in SARS-CoV-2 Spike MESHD Protein

    Authors: Lorenzo Casalino; Zied Gaieb; Abigail C. Dommer; Aoife M. Harbison; Carl A. Fogarty; Emilia P. Barros; Bryn C. Taylor; Elisa Fadda; Rommie E. Amaro

    doi:10.1101/2020.06.11.146522 Date: 2020-06-11 Source: bioRxiv

    The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) has resulted in more than 7,000,000 infections and 400,000 deaths worldwide to date. Antibody SERO development efforts mainly revolve around the extensively glycosylated SARS-CoV-2 spike MESHD (S) protein, which mediates the host cell entry by binding to the angiotensin-converting enzyme 2 (ACE2). In the context of vaccine design, similar to many other viruses, the SARS-CoV-2 spike utilizes a glycan shield to thwart the host immune response. Here, we built a full-length model of glycosylated SARS-CoV-2 MESHD S protein, both in the open and closed states, augmenting the available structural and biological data. Multiple microsecond-long, all-atom molecular dynamics simulations were used to provide an atomistic perspective on the glycan shield and the protein structure, stability, and dynamics. End-to-end accessibility analyses outline a complete overview of the vulnerabilities of the glycan shield of SARS-CoV-2 S protein, which can be harnessed for vaccine development. In addition, a dynamic analysis of the main antibody SERO epitopes is provided. Finally, beyond shielding, a possible structural role of N-glycans at N165 and N234 is hypothesized to modulate and stabilize the conformational dynamics of the spikes receptor binding domain, which is responsible for ACE2 recognition. Overall, this work presents hitherto unseen functional and structural insights into the SARS-CoV-2 S protein and its glycan coat, which may be exploited by therapeutic efforts targeting this essential molecular machine.

    Theoretical Study of the Optical Spectra of SARS-CoV-2 Proteins MESHD

    Authors: Zhuo Li; Jonathan Hirst

    doi:10.26434/chemrxiv.12451922.v1 Date: 2020-06-11 Source: ChemRxiv

    Treatment for severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), the virus that causes Covid-19, may well be predicated on knowledge of the structures of protein of this virus. However, often these cannot be determined easily or quickly. Herein, we provide calculated circular dichroism (CD) spectra in the far- and near-UV, and infra-red (IR) spectra in the amide I region for experimental structures and computational models of SARS-CoV-2 proteins MESHD. The near-UV CD spectra offer greatest sensitivity SERO in assessing the accuracy of models.

    Clinical characteristics of SARS-CoV-2 patients: a French cross-sectional study in primary care

    Authors: Paul Sebo; Benoit Tudrej; Julie Lourdaux; Clara Cuzin; Martin Floquet; Dagmar M Haller; Hubert Maisonneuve

    doi:10.21203/rs.3.rs-34635/v1 Date: 2020-06-11 Source: ResearchSquare

    Background: The early identification of patients suffering from SARS-CoV-2 infection MESHD in primary care is of outmost importance in the current pandemic.Aim: To gain a better understanding of the specific symptoms of SARS-CoV-2 infection MESHD in primary care.Design and setting: We conducted a cross-sectional study between March 24 and May 7, 2020, involving consecutive patients undergoing RT-PCR testing in two community-based laboratories in Lyon (France) for a suspicion of COVID-19.Methods: We examined the association between various symptoms and a positive test using univariate and multivariate logistic regression, adjusted for clustering within the laboratories.Results: Of the 1561 patients tested, 1543 agreed to participate (participation rate: 99%). Among them, 253 were positive for SARS-Cov-2 (16%). In multivariate analysis, loss of taste (OR 3.8 [95%CI 3.3-4.4], p-value<0.001), loss of smell (OR 3.0 [95%CI 1.9-4.8], p-value<0.001), muscle pain MESHD pain HP (OR 1.6 [95%CI 1.2-2.0], p-value 0.001) and dry nose (OR 1.3 [95%CI 1.1-1.6], p-value 0.01) were significantly associated with a positive result. The strength of association with taste and smell disorders was higher for symptom combinations (OR 6.5 [95%CI 3.9-10.8] for loss of taste MESHD and smell, OR 6.7 [95%CI 5.9-7.5] for loss of taste MESHD or smell). In contrast, sore throat (OR 0.6 [95%CI 0.4-0.8], p-value 0.003), stuffy nose (OR 0.7 [95%CI 0.6-0.7], p-value<0.001), diarrhea HP diarrhea MESHD (OR 0.6 [95%CI 0.5-0.6], p-value<0.001) and dyspnea HP dyspnea MESHD (OR 0.5 [95%CI 0.3-0.7], p-value<0.001) were inversely associated with a positive test.Conclusion: Our data could further facilitate targeted screening and contribute to the triage and early identification of new clusters of cases.

    Hijacking SARS-Cov-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on receptor binding region

    Authors: Adriana Carino; Federica Moraca; Bianca Fiorillo; Silvia Marcanó; Valentina Sepe; Michele Biagioli; Claudia Finamore; Silvia Bozza; Daniela Francisci; Eleonora Distrutti; Bruno Catalanotti; Angela Zampella; Stefano Fiorucci

    doi:10.1101/2020.06.10.144964 Date: 2020-06-11 Source: bioRxiv

    The coronavirus disease MESHD 2019 (COVID-19) is a respiratory tract infection HP respiratory tract infection MESHD caused by the severe acute respiratory syndrome coronavirus (SARS)-CoV-2 MESHD. In the light of the urgent need to identify novel approaches to be used in the emergency phase, a largely explored strategy has been the repurpose of clinically available drugs as new antivirals, by targeting different viral proteins. In this paper, we describe a drug repurposing strategy based on a virtual screening of druggable pockets located in the central β-sheet core of the SARS-CoV-2 Spike MESHD protein RBD supported by in vitro tests identifying several steroidal derivatives as SARS-CoV-2 entry inhibitors. Our results demonstrate that several potential binding sites exist in the SARS CoV-2 S protein, and that the occupancy of these pockets reduces the ability of the S protein RBD to bind to the ACE2 consensus in vitro. In particular, natural occurring and clinically available steroids as glycyrrhetinic and oleanolic acids, as well as the bile acids derivatives glyco-UDCA and obeticholic acid have been shown to be effective in preventing virus entry in the case of low viral load. All together, these results might help to define novel approaches to reduce the viral load by using SARS-CoV-2 entry inhibitors.Competing Interest StatementThis paper was supported by a research grant by BAR Pharmaceuticals S.r.L. to the Department of Pharmacy of the University of Napoli Federico II and to the Department of Surgical and Biomedical Sciences, University of Perugia. The authors declare the following competing financial interest(s): S.F., A.Z. and B.C. have filed an Italian patent application no.102020000011092 in the name of BAR Pharmaceuticals S.r.L. on the compounds described in this paper. View Full Text

    Inflammatory cytokines depletion for severe COVID-19 infectious pneumonia MESHD pneumonia HP: a case report

    Authors: Bo Yang; Jing Yang; Lan Zhou; Cheng Xue; Hongxian Li; Weifeng Hu; Nanmei Liu

    doi:10.21203/rs.3.rs-34626/v1 Date: 2020-06-11 Source: ResearchSquare

    BackgroundIn the severe infected COVID-19 patients, besides the viral pneumonia MESHD pneumonia HP, multi-organ/system injury could be observed. Recognizing and correcting the key and immediate dysfunctions may reduce the mortality.Case presentationHere, we report a male TRANS patient with severe SARS-CoV-2 infection MESHD from isolation Ward- Guanggu Branch of Hubei Province Maternity and Childcare Hospital, who is treated with combined inflammatory cytokines depletion therapy and convalescent plasma SERO. The multi-modal therapy ultimately resulted in improvement of respiratory function and removal from mechanical ventilation. The case of ARDS with severe SARS-CoV-2 infection MESHD indicated the potential benefit of convalescent plasma SERO and inflammatory cytokines depletion through combined measurements including double filtration plasma SERO pheresis and Tocilizumab.ConclusionIt is not safe to draw causal conclusions between cytokine depletion and clinical manifestations improvement with only one case, while this would be a potential research direction in facing the COVID-19 crisis.

    Network analysis of Down syndrome and SARS-CoV-2 identifies risk and protective factors for COVID-19

    Authors: Ilario De Toma; Mara Dierssen

    doi:10.21203/rs.3.rs-34625/v1 Date: 2020-06-11 Source: ResearchSquare

    Background: SARS-CoV-2 has spread uncontrollably worldwide while we still ignore how particularly vulnerable populations, such as Down syndrome ( DS MESHD) individuals are affected by the COVID-19 pandemic. Individuals with DS have more risk of infections TRANS risk of infections TRANS infections MESHD with respiratory complications MESHD and present signs of auto-inflammation MESHD. They also suffer from multiple comorbidities that are associated with poorer COVID-19 prognosis in the general population. All this might place DS individuals at higher risk of SARS-CoV-2 infection MESHD or poorer clinical outcomes.Methods: In order to get insight into the interplay between DS genes and SARS-cov2 infection MESHD and pathogenesis we retrieved the genes belonging to the molecular pathways involved in COVID-19 and the host proteins interacting with viral proteins from SARS-CoV-2. We therefore analyzed the overlaps of these genes with HSA21 genes, HSA21 interactors and other genes consistently differentially expressed in DS (using public transcriptomic datasets) creating a DS-SARS-CoV-2 network.Results: We detected COVID-19 protective and risk factors that might affect the susceptibility of individuals with DS both at the infection stage and in the progression to acute respiratory distress HP respiratory distress MESHD syndrome.Conclusion: Our analysis suggests that at the infection stage DS individuals might be more susceptible to infection due to triplication of TMPRSS2, that primes the viral S protein for entry in the host cells, even though the anti-viral interferon I signaling is upregulated in DS and this might increase the initial anti-viral response. In the second pro-inflammatory immunopathogenic phase of the infection MESHD, the prognosis for DS patients might worsen due to upregulation of inflammatory genes that might favor the typical cytokine storm of COVID-19. We also detected strong downregulation of the NLRP3 gene, critical for maintenance of homeostasis against pathogenic infections, possibly leading to bacterial infection complications MESHD.

    Remdesivir but not famotidine inhibits SARS-CoV-2 replication in human pluripotent stem cell-derived intestinal organoids

    Authors: Jan Krueger; Ruediger Gross; Carina Conzelmann; Janis A Mueller; Lennart Koepke; Konstantin Sparrer; Desiree Schuetz; Thomas Seufferlein; Thomas F.E. Barth; Steffen Stenger; Sandra Heller; Alexander Kleger; Jan Muench

    doi:10.1101/2020.06.10.144816 Date: 2020-06-11 Source: bioRxiv

    Gastrointestinal symptoms in COVID-19 are associated with prolonged symptoms and increased severity. We employed human intestinal organoids derived from pluripotent stem cells ( PSC-HIOs MESHD) to analyze SARS-CoV-2 pathogenesis and to validate efficacy of specific drugs in the gut. Certain, but not all cell types in PSC-HIOs MESHD express SARS-CoV-2 entry factors ACE2 and TMPRSS2, rendering them susceptible to SARS-CoV-2 infection MESHD. Remdesivir, a promising drug to treat COVID-19, effectively suppressed SARS-CoV-2 infection of PSC-HIOs MESHD. In contrast, the histamine-2-blocker famotidine showed no effect. Thus, PSC-HIOs MESHD provide an interesting platform to study SARS-CoV-2 infection MESHD and to identify or validate drugs.

    A Comprehensive Review of the Cross-Disciplinary Impact of COVID-19 in India

    Authors: Pranjali Dhawal; Shruti Kakodkar; Rasika Pawar; Shraddha Bhome; Siddhivinayak Barve

    id:10.20944/preprints202006.0131.v1 Date: 2020-06-11 Source: Preprints.org

    A novel coronavirus (2019-nCoV) responsible for a severe acute respiratory disorder MESHD (SARS-CoV-2) in humans, with its epicentre in Wuhan, China emerged in December 2019. This coronavirus, by far, has hit >200 countries, affecting 7 million worldwide accounting 11% death of the affected population. The transmission TRANS is majorly caused by human-to-human contact and, through fomite TRANS. In view of the increasing number of COVID-19 cases and the absence of definitive treatment or vaccinations, WHO has deemed the viral infection a pandemic of international concern. In such grave situations, there is a need for expanding the health sector workforce, government and police workforce, sanitation and prevention strategies. The current article describes the virology aspect, control of COVID-19 and revisits the various treatment options available at present this deadly infection. Epidemiology of COVID-19 is also discussed to further understand the pandemic status of India. The article also discusses implicating quarantine or social distancing, and in extreme cases, lockdown or alternative approaches such as herd or indirect immunity, as a measure to control the pandemic. Lockdown or social distancing will give rise to economic, emotional, political and social downfall in the country. It is estimated that a lockdown period will set back the country, possibly, by $240 billion, yet it stands unavoidable in the spread of control of infection MESHD. Thus, policymakers should strategize economic revival depending upon the best possible data and critical understanding.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.